481 related articles for article (PubMed ID: 33907949)
1. A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir.
Huang PY; Chiu SY; Chang KC; Tseng PL; Yen YH; Tsai MC; Wang JH; Kee KM; Chen CH; Hung CH; Chiu KW; Hu TH
Hepatol Int; 2021 Apr; 15(2):310-317. PubMed ID: 33907949
[TBL] [Abstract][Full Text] [Related]
2. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling.
Tien C; Xu JJ; Chan LS; Chang M; Lim C; Lee S; Huh B; Shinada S; Bae HS; Fong TL
Dig Dis Sci; 2015 Feb; 60(2):566-72. PubMed ID: 25239496
[TBL] [Abstract][Full Text] [Related]
4. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Liu Z; Zhao Z; Ma X; Liu S; Xin Y
BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
[TBL] [Abstract][Full Text] [Related]
5. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study.
Lampertico P; Berg T; Buti M; Pathil A; Petersen J; Ryder SD; Zoulim F; Botros I; Flaherty JF; Jump B; Op den Brouw ML; van Troostenburg A; Ramroth H;
Aliment Pharmacol Ther; 2020 Aug; 52(3):500-512. PubMed ID: 32583915
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study.
Mak LY; Hoang J; Jun DW; Chen CH; Peng CY; Yeh ML; Kim SE; Huang DQ; Jeong JY; Yoon E; Oh H; Tsai PC; Huang CF; Ahn SB; Trinh H; Xie Q; Wong GLH; Enomoto M; Shim JJ; Lee DH; Liu L; Kozuka R; Cho YK; Jeong SW; Kim HS; Trinh L; Dao A; Huang R; Hui RW; Tsui V; Quek S; Khine HHTW; Ogawa E; Dai CY; Huang JF; Cheung R; Wu C; Chuang WL; Lim SG; Yu ML; Yuen MF; Nguyen MH
Hepatol Int; 2022 Feb; 16(1):48-58. PubMed ID: 34822056
[TBL] [Abstract][Full Text] [Related]
7. Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir.
Da Wang F; Zhou J; Li LQ; Li YJ; Wang ML; Tao YC; Zhang DM; Wang YH; Chen EQ
Ann Hepatol; 2023; 28(5):101119. PubMed ID: 37271480
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis.
Chen J; Zhao SS; Liu XX; Huang ZB; Huang Y
Clin Ther; 2017 Sep; 39(9):1870-1880. PubMed ID: 28797777
[TBL] [Abstract][Full Text] [Related]
9. Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study.
Rodríguez-Nóvoa S; García-Samaniego J; Prieto M; Calleja JL; Pascasio JM; Delgado Blanco M; Crespo J; Buti M; Bonet Vidal ML; Arenas Ruiz Tapiador J; Fernández-Rodríguez C; Solá R; Fraga E; González Diéguez L; Núñez O; Praga M; Del Pino-Montes J; Romero-Gómez M; Morillas R; Diago M; Castro Á;
J Clin Gastroenterol; 2016 Oct; 50(9):779-89. PubMed ID: 27332746
[TBL] [Abstract][Full Text] [Related]
10. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial.
Iida-Ueno A; Enomoto M; Kozuka R; Tamori A; Kawada N
J Med Virol; 2019 Jul; 91(7):1295-1300. PubMed ID: 30815880
[TBL] [Abstract][Full Text] [Related]
11. Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B.
Wei MT; Le AK; Chang MS; Hsu H; Nguyen P; Zhang JQ; Wong C; Wong C; Cheung R; Nguyen MH
J Med Virol; 2019 Jul; 91(7):1288-1294. PubMed ID: 30776311
[TBL] [Abstract][Full Text] [Related]
12. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
[No Abstract] [Full Text] [Related]
13. Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease.
Tsai HJ; Chuang YW; Yang SS; Chang YZ; Chang HR; Lee TY
J Viral Hepat; 2021 Nov; 28(11):1579-1586. PubMed ID: 34464999
[TBL] [Abstract][Full Text] [Related]
14. Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: a systematic review and meta-analysis.
Yang X; Yan H; Zhang X; Qin X; Guo P
Int J Infect Dis; 2022 Nov; 124():133-142. PubMed ID: 36122671
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
Wang YH; Liao J; Zhang DM; Wu DB; Tao YC; Wang ML; Chen EQ; Tang H
J Med Virol; 2020 Mar; 92(3):302-308. PubMed ID: 31609007
[TBL] [Abstract][Full Text] [Related]
16. Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir.
Trinh S; Le AK; Chang ET; Hoang J; Jeong D; Chung M; Lee MH; Wang U; Henry L; Cheung R; Nguyen MH
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):948-956.e1. PubMed ID: 30130625
[TBL] [Abstract][Full Text] [Related]
17. Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B.
Yip TC; Lai JC; Yam TF; Tse YK; Hui VW; Lai MS; Chan HL; Wong VW; Wong GL
J Hepatol; 2024 Apr; 80(4):553-563. PubMed ID: 38101755
[TBL] [Abstract][Full Text] [Related]
18. Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose, and uric acid in chronic hepatitis B patients.
Zhang Q; Liang J; Yin J; Jiang Y; Yu N; Liao X; Zhao S; Wu L; Fan R
J Med Virol; 2022 Nov; 94(11):5465-5474. PubMed ID: 35794065
[TBL] [Abstract][Full Text] [Related]
19. Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis.
Lee HY; Oh H; Park CH; Yeo YH; Nguyen MH; Jun DW
World J Gastroenterol; 2019 Jun; 25(23):2961-2972. PubMed ID: 31249453
[TBL] [Abstract][Full Text] [Related]
20. Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study.
Chon YE; Park SY; Kim SU; Hong HP; Lee JS; Lee HW; Kim MN; Park JY; Kim DY; Ahn SH; Kim BK
J Viral Hepat; 2022 Apr; 29(4):289-296. PubMed ID: 35152517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
